Bupropion Hydrobromide Polymorphs for Alcohol-Resistant Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bupropion hydrochloride formulations are prone to instability and seizures when stored under certain conditions, and they do not provide a stable and effective release profile, particularly in the presence of alcohol.
Innovation Solution
Development of new crystalline forms of bupropion hydrobromide (Forms IV, V, VI, and VII) and their amorphous form, which are more stable and less likely to cause seizures, along with controlled release formulations that include a core of bupropion hydrobromide with a binder and lubricant, surrounded by a controlled release coat, providing a stable and prolonged release profile resistant to dose dumping in high alcohol concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bupropion hydrochloride formulations are used, then immediate release and sustained release effects are achieved, but stability and seizure risk worsen under certain storage conditions
Solution Approach 1:
The patent changes the chemical parameter from bupropion hydrochloride to bupropion hydrobromide, which fundamentally alters the stability profile and seizure threshold characteristics of the formulation, thereby resolving the contradiction between achieving release effects and maintaining stability
Solution Approach 2:
The patent employs composite material strategies by combining bupropion hydrobromide with specific excipients and polymers in controlled release formulations, creating a stable matrix system that maintains drug stability while controlling release kinetics and reducing seizure risk
2Reliability
If conventional bupropion formulations are used, then drug release is achieved, but release profile stability worsens in the presence of alcohol
Solution Approach 1:
The patent converts the harmful effect of alcohol on drug release by using alcohol-resistant polymer matrices that actually improve release profile stability in the presence of alcohol, turning the previously problematic condition into a validated performance characteristic
Solution Approach 2:
The patent uses flexible polymer coating systems that can accommodate the presence of alcohol without compromising the controlled release mechanism, maintaining stable drug delivery even when exposed to high alcohol concentrations
3Speed
If immediate release formulations are used, then quick drug availability is achieved, but dosing frequency and complexity increase
Solution Approach 1:
The patent transitions from static immediate release to dynamic controlled release systems that adapt drug release rates to maintain therapeutic levels throughout the day, enabling once-daily dosing while preserving effective drug availability
Solution Approach 2:
The patent incorporates preliminary action by designing formulations that pre-establish controlled release mechanisms, allowing the drug to be released at optimal rates over extended periods, thereby reducing dosing frequency while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new bupropion hydrobromide formulations exhibit enhanced stability and reduced seizure incidence, with a controlled release profile that maintains therapeutic levels of bupropion over a 24-hour period, even in the presence of high alcohol concentrations, ensuring bioequivalence to existing formulations like WELLBUTRIN™ and ZYBAN™.
Implementation Method 1
controlled release coat... providing a stable and prolonged release profile resistant to dose dumping in high alcohol concentrations
Implementation Method 2
controlled release coat... providing a stable and prolonged release profile resistant to dose dumping in high alcohol concentrations
Data Source
AI summary
Polymorphous and amorphous forms of bupropion hydrobromide are described.